Biotech company Nextgen, a member of the Artgen Biotech Group (MOEX: ABIO), has become a member of the Chamber of Commerce and Industry of the Russian Federation. It is not only recognition of the company’s importance at the federal level, but also additional support in resolving production and regulatory issues in Russia, as well as an opportunity to establish business relations with foreign partners.
Membership in the Chamber of Commerce and Industry of the Russian Federation indicates the company’s goodwill.
Nextgen is currently actively negotiating with EAEU states, Kuwait and India, on the export of Neovasculgen, the world’s first gene therapy drug based on “therapeutic angiogenesis” (therapeutic growth of blood vessels), to these countries.
The Russian Chamber of Commerce and Industry is the main platform for interaction between government bodies and businesses. The main goals of the Chamber are to protect entrepreneurs’ interests with government bodies, build a dialog with business, unite specialized companies into business communities, and inform them about new government initiatives.
NextGen, JSC is a resident of Medtech, the Lomonosov Cluster of the Vorobyovy Gory MSU Innovative Technology Research Center. The company develops and implements gene therapy drugs, expands the indications for use of Neovasculgen.